The chart below tracks actual sales vs. average sales. The value in this chart is that it demonstrates the dynamics of why the street is not very excited about MannKind stock, and in fact the bears are currently at an …
NASDAQ
Matthew Pfeffer, CEO of MannKind Corporation displays the Afrezza inhaler in the company's Valencia office. Photo by Jonathan Pobre. …
The Santa Clarita Valley Signal
First, the bad news. MannKind's share price has been below $1 for most of the past six months. If the stock price doesn't rise above $1 for at least …
MannKind
Biotech stock MannKind (MNKD) is trading on the absolute cheap right now, so any investors with a high tolerance for risk now have a unique opportunity at their doorstep. What kind of risk are we talking about? …
Stock
MannKind Corporation is having a rough day in the market today, and for good reason. Yesterday, after the closing bell, the company made an announcement that proved to be a concern. Below, we'll talk about the …
Reverse
Investors in MannKind Corp (NASD: MNKD) saw new options begin trading today, for the January 2014 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNKD options …
The MannKind Corporation (NASDAQ: MNKD) stock price is down 28% over the last six months as of August 2016. The stock has experienced tremendous volatility over this time period, as it continues to run low on …
Stock
In a report published on Tuesday, Goldman Sachs downgraded MannKind Corporation (NASDAQ:MNKD) stock from a Neutral to a Sell rating, and cut the price target from $6 to $3. As the news crossed the wires, the …
As of late, it has definitely been a great time to be an investor in MannKind Corporation . The stock has moved higher by 38.7% in the past month, while it is also above its 20 Day SMA too. This combination of strong price …
ZACKS1mon